In the Pipeline

If you have any questions, please reach out at [email protected] or on Twitter/X @tdonatellov. Thank you for listening!Sources:Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic CancerIDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal MelanomaAllogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCLGSK presents positive data for B7-H4-targeted ADC in gynecological cancersCorrections:Stated that there are >300 primary uveal melanona cases annually in the U.S., this figure is actually >3000 cases. Did not mention that the OptimUM-02 trial of darovasertib + crizotinib included 437 patients randomized 2:1 to darovasertib + crizotinib or investigator's choice

If you have any questions, please reach out at [email protected] or on Twitter/X @tdonatellov. Thank you for listening!Topics:CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal CancerBristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple MyelomaRelmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder CancerGenentech Provides Update on Phase III persevErA Study in ER-Positive Advanced Breast CancerPfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

If you have any questions, please reach out at [email protected] or on Twitter/X @tdonatellov. Thank you for listening!Topics:Ph III (lidERA) giredestrant in adjuvant ER+/HER2-negative, early BCTERN-701 CARDINAL Trial December 2025 Data UpdateJANX007 Phase 1 Clinical Update

If you have any questions, please reach out at [email protected]. Thank you for listening!Topics:Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 studyPrimary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentMinimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

If you have any questions, please reach out at [email protected]. Thank you for listening!Topics:Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 MonthsRelmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder CancerUpdate on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study

The first episode of the relaunched podcast, focusing exclusively on oncology/hematology.If you have any questions, please reach out at [email protected]. Thank you for listening!Topics:Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted CancersHalda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistance Prostate Cancer (mCRPC)

Thank you for checking out the first episode of the podcast! If you have any questions or corrections you would like for me to address you can reach me in the following ways:Email: [email protected]/X: tdonatellov